ESVAL KEVIN JAMES 4
4 · Exactus, Inc. · Filed Nov 22, 2019
Insider Transaction Report
Form 4
Exactus, Inc.EXDI
ESVAL KEVIN JAMES
Director
Transactions
- Award
Common Stock
2019-11-20+100,000→ 100,250 total
Holdings
- 425,000(indirect: 237,500(2) shares held by VelocityHealth Capital; 187,500(2) shares held by Donegal Bio Ventures)
Common Stock
- 250,000
Options to purchase common stock
Exercise: $0.20From: 2019-01-11Exp: 2029-01-11→ Common Stock (250,000 underlying) - 168,000(indirect: Held by VelocityHealth Capital)
Series B-2 Preferred Stock
From: 2019-01-11Exp: 2050-01-17→ Common Stock (168,000 underlying)
Footnotes (3)
- [F1]Award of restricted common stock that vests equally over 24 months commencing the date of grant, subject to the reporting person's continued service as director.
- [F2]Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019.
- [F3]Shares of Series B-2 preferred stock are convertible into shares of common stock at a conversion rate of 0.125 shares of common stock for every 1 share of Series B-2 preferred stock.